TY  - JOUR
AU  - Hoenig, Merle C
AU  - Dzialas, Verena
AU  - Doering, Elena
AU  - Bischof, Gérard N
AU  - Eimeren, Thilo
AU  - Drzezga, Alexander
TI  - Modifiable Factors Associated with the Longitudinal Increase and Spatial Extent of Tau Pathology in Alzheimer Disease.
JO  - Journal of nuclear medicine
VL  - 67
IS  - 2
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DZNE-2026-00143
SP  - 291-296
PY  - 2026
AB  - There are 14 modifiable factors that are associated with a significantly lower risk of dementia. We tested the interactive effect of modifiable factors, genetic determinants, and initial pathologic burden on the spatial progression and local amplification of tau pathology. Methods: In total, 162 amyloid-positive individuals were included, for whom longitudinal [18F]AV-1451 PET scans, baseline information on global amyloid burden, ApoE4 status, body mass index (BMI), hypertension, education, neuropsychiatric symptom severity, and demographic information were available in the Alzheimer Disease Neuroimaging Initiative. All [18F]AV-1451 scans were intensity-standardized (reference: inferior cerebellum), z-transformed (control sample: 147 amyloid-negative subjects), thresholded (z score, >1.96), and converted to volume maps. Longitudinal tau changes were then assessed in terms of tau spatial extent (i.e., newly affected volume at follow-up) and tau level rise (i.e., tau increase in previously affected volume). These 2 measures were entered as dependent variables in linear mixed-effects models, including baseline modifiable risk factors (BMI, education, hypertension, neuropsychiatric symptom severity), global amyloid, tau volume or tau burden, ApoE4 status, clinical stage, sex, and age as predictors. Next, we tested the interactive effects between baseline amyloid or tau burden with the 4 modifiable factors on tau extent or tau level rise, respectively. Results: Greater tau extent was linked to higher BMI (β = 0.002; 95
KW  - Humans
KW  - tau Proteins: metabolism
KW  - Male
KW  - Alzheimer Disease: diagnostic imaging
KW  - Alzheimer Disease: metabolism
KW  - Alzheimer Disease: pathology
KW  - Female
KW  - Aged
KW  - Longitudinal Studies
KW  - Positron-Emission Tomography
KW  - Carbolines
KW  - Aged, 80 and over
KW  - Middle Aged
KW  - Body Mass Index
KW  - Risk Factors
KW  - (non-)modifiable risk factors (Other)
KW  - spatial extent (Other)
KW  - tau pathology (Other)
KW  - tau Proteins (NLM Chemicals)
KW  - 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (NLM Chemicals)
KW  - Carbolines (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41266256
C2  - pmc:PMC12866421
DO  - DOI:10.2967/jnumed.125.270593
UR  - https://pub.dzne.de/record/285017
ER  -